{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:40:00Z","timestamp":1791884400569,"version":"4.3.4"},"reference-count":111,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.kint.2018.10.018","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T05:12:10Z","timestamp":1547788330000},"page":"268-280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":228,"title":["Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference"],"prefix":"10.1016","volume":"95","author":[{"given":"J\u00fcrgen","family":"Floege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Barbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Cattran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick H.","family":"Nachman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney C.W.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5272-425X","authenticated-orcid":false,"given":"Wolfgang C.","family":"Winkelmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad H.","family":"Rovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon G.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Alpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn J.","family":"Caster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Chon Jun","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Terence","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes B.","family":"Fogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisha L.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Glassock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth M.","family":"Hodson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elion","family":"Hoxha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunitoshi","family":"Iseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Charles","family":"Jennette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanand","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kaname","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuko","family":"Katafuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Richard","family":"Kitching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Lafayette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip K.T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jicheng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Malvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Mej\u00eda-Vilet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J.","family":"Moeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Chiu","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla M.","family":"Nester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisei","family":"Noiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"O'Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seza","family":"\u00d6zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir M.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong-Cheon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen Au","family":"Peh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Pendergraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evang\u00e9line","family":"Pillebout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Smoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Tesa\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Thurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hern\u00e1n","family":"Trimarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Vivarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles D.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Yee-Moon","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Wenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2018.10.018_bib1","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kint.2018.10.018_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.kint.2017.01.002","article-title":"A\u00a0proposal for standardized grading of chronic changes in native kidney biopsy specimens","volume":"91","author":"Sethi","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib3","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1053\/j.ajkd.2012.12.019","article-title":"The rise of renal pathology in nephrology: structure illuminates function","volume":"61","author":"D'Agati","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.10.018_bib4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/modpathol.2012.207","article-title":"Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies","volume":"26","author":"Larsen","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kint.2018.10.018_bib5","doi-asserted-by":"crossref","first-page":"8803","DOI":"10.1038\/srep08803","article-title":"Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis","volume":"5","author":"Dai","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2018.10.018_bib6","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1681\/ASN.2014080752","article-title":"Glomerular aging and focal global glomerulosclerosis: a podometric perspective","volume":"26","author":"Hodgin","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib7","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A\u00a0proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/ndt\/gfu035","article-title":"Focal segmental glomerulosclerosis: towards a better understanding for the practicing nephrologist","volume":"30","author":"Sethi","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.10.018_bib10","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.kint.2016.06.020","article-title":"The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases","volume":"90","author":"Hogan","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib11","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib12","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2018.10.018_bib13","doi-asserted-by":"crossref","first-page":"c177","DOI":"10.1159\/000232599","article-title":"Random spot urine protein\/creatinine ratio is unreliable for estimating 24-hour proteinuria in individual systemic lupus erythematosus nephritis patients","volume":"113","author":"Hebert","year":"2009","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.kint.2018.10.018_bib14","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1681\/ASN.2018020160","article-title":"A\u00a0novel method for rapid bedside measurement of GFR","volume":"29","author":"Rizk","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2215\/CJN.05030610","article-title":"Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration","volume":"6","author":"Ix","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib16","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ki.2012.388","article-title":"Comparison of the glomerular filtration rate in children by the new revised Schwartz formula and a new generalized formula","volume":"83","author":"Gao","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib17","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2215\/CJN.01640309","article-title":"Measurement and estimation of GFR in children and adolescents","volume":"4","author":"Schwartz","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/ndt\/gfh719","article-title":"Serum creatinine is a poor marker of GFR in nephrotic syndrome","volume":"20","author":"Branten","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.10.018_bib19","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1681\/ASN.2009020171","article-title":"Measured GFR as a confirmatory test for estimated GFR","volume":"20","author":"Stevens","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1053\/j.ajkd.2011.09.021","article-title":"Comparison of concurrent complications of CKD by 2 risk categorization systems","volume":"59","author":"Inker","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.10.018_bib21","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/sim.5654","article-title":"Nonparametric ROC summary statistics for correlated diagnostic marker data","volume":"32","author":"Tang","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.kint.2018.10.018_bib22","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3899\/jrheum.111608","article-title":"Persistent or new onset microscopic hematuria in patients with small vessel vasculitis in remission: findings on renal biopsy","volume":"39","author":"Geetha","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.kint.2018.10.018_bib23","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1681\/ASN.2017010108","article-title":"Remission of hematuria improves renal survival in IgA nephropathy","volume":"28","author":"Sevillano","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib24","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.10.018_bib25","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1681\/ASN.2015010091","article-title":"Complete and partial remission as surrogate end points in membranous nephropathy","volume":"26","author":"Thompson","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1681\/ASN.2015111262","article-title":"Membranous nephropathy: quantifying remission duration on outcome","volume":"28","author":"Cattran","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib27","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1681\/ASN.2016101089","article-title":"Magnetic resonance imaging of the fibrotic kidney","volume":"28","author":"Morrell","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib28","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1046\/j.1523-1755.2001.0590041211.x","article-title":"Renoprotection: one or many therapies?","volume":"59","author":"Hebert","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib29","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00467-011-1843-8","article-title":"Human nephron number: implications for health and disease","volume":"26","author":"Bertram","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib30","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ekir.2017.05.002","article-title":"Association of sleep duration, symptoms, and disorders with mortality in adults with chronic kidney disease","volume":"2","author":"Ricardo","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2018.10.018_bib31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/ajkd.2003.50039","article-title":"Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies","volume":"41","author":"Morales","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.10.018_bib32","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/ndt\/gfp640","article-title":"Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts","volume":"25","author":"Afshinnia","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.10.018_bib33","first-page":"200","article-title":"The beneficial effects of weight reduction in overweight patients with chronic proteinuric immunoglobulin a nephropathy: a randomized controlled trial","volume":"24","author":"Kittiskulnam","year":"2014","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.kint.2018.10.018_bib34","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/ndt\/gfm919","article-title":"The impact of sex in primary glomerulonephritis","volume":"23","author":"Cattran","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.10.018_bib35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00467-014-2857-9","article-title":"Defining nephrotic syndrome from an integrative genomics perspective","volume":"30","author":"Sampson","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib36","doi-asserted-by":"crossref","unstructured":"Preston R, Stuart HM, Lennon R. Genetic testing in steroid-resistant nephrotic syndrome: why, who, when and how? [e-pub ahead of print]. Pediatr Nephrol. https:\/\/doi.org\/10.1007\/s00467-017-3838-6. Accessed December 15, 2018.","DOI":"10.1007\/s00467-017-3838-6"},{"key":"10.1016\/j.kint.2018.10.018_bib37","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1093\/ndt\/gfs384","article-title":"Resistant hypertension and the neglected antihypertensive: sodium restriction","volume":"27","author":"Agarwal","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.10.018_bib38","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1056\/NEJMoa0907355","article-title":"Projected effect of dietary salt reductions on future cardiovascular disease","volume":"362","author":"Bibbins-Domingo","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.10.018_bib39","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jash.2017.07.006","article-title":"Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study","volume":"11","author":"Voskamp","year":"2017","journal-title":"J\u00a0Am Soc Hypertens"},{"key":"10.1016\/j.kint.2018.10.018_bib40","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jchf.2017.05.012","article-title":"Aldosterone, renin, cardiovascular events, and all-cause mortality among African Americans: the Jackson Heart Study","volume":"5","author":"Joseph","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.kint.2018.10.018_bib41","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.2215\/CJN.00390117","article-title":"Pooled analysis of multiple crossover trials to optimize individual therapy response to renin-angiotensin-aldosterone system intervention","volume":"12","author":"Petrykiv","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/07853890.2017.1313447","article-title":"Effects of direct renin inhibition versus angiotensin II receptor blockade on angiotensin profiles in non-diabetic chronic kidney disease","volume":"49","author":"Antlanger","year":"2017","journal-title":"Ann Med"},{"key":"10.1016\/j.kint.2018.10.018_bib43","doi-asserted-by":"crossref","first-page":"F412","DOI":"10.1152\/ajprenal.00445.2017","article-title":"Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study","volume":"314","author":"Rajasekeran","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2018.10.018_bib44","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1053\/j.ajkd.2015.12.030","article-title":"Controversies regarding lipid management and statin use for cardiovascular risk reduction in patients with CKD","volume":"67","author":"Markossian","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.10.018_bib45","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.kint.2015.12.041","article-title":"Patients with primary membranous nephropathy are at high risk of cardiovascular events","volume":"89","author":"Lee","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib46","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.10.018_bib47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00467-012-2323-5","article-title":"Hyperlipidemia, oxidative stress, and intima media thickness in children with chronic kidney disease","volume":"28","author":"Kotur-Stevuljevic","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib48","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1681\/ASN.2013090965","article-title":"Effects of lowering LDL cholesterol on progression of kidney disease","volume":"25","author":"Haynes","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib49","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/ki.2013.476","article-title":"Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy","volume":"85","author":"Lee","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib50","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/ki.2011.312","article-title":"Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis","volume":"81","author":"Barbour","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib51","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/ndt\/gfx322","article-title":"Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation","volume":"33","author":"Stamellou","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.10.018_bib52","first-page":"480","article-title":"Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review","volume":"31","author":"Cholongitas","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.kint.2018.10.018_bib54","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.kint.2016.09.010","article-title":"Management of patients with diabetes and CKD: conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference","volume":"90","author":"Perkovic","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib55","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.kint.2017.06.018","article-title":"Common elements in rare kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"92","author":"Ayme","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib56","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2012.428","article-title":"Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach","volume":"83","author":"Gadegbeku","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib57","doi-asserted-by":"crossref","first-page":"316ra193","DOI":"10.1126\/scitranslmed.aac7071","article-title":"Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker","volume":"7","author":"Ju","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.kint.2018.10.018_bib58","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/ki.2011.501","article-title":"An update on the pathogenesis and treatment of IgA nephropathy","volume":"81","author":"Boyd","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib59","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00467-017-3699-z","article-title":"New insights into the pathogenesis of IgA nephropathy","volume":"33","author":"Yeo","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib60","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1681\/ASN.2012010053","article-title":"Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy","volume":"23","author":"Berthoux","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib61","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/ndt\/gfv221","article-title":"Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy","volume":"30","author":"Yasutake","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.10.018_bib62","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2018.10.018_bib63","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstrom","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.10.018_bib64","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1681\/ASN.2007121311","article-title":"Toll-like receptor 9 affects severity of IgA nephropathy","volume":"19","author":"Suzuki","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib65","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.humimm.2015.09.044","article-title":"Genetic polymorphisms in TNFSF13 and FDX1 are associated with IgA nephropathy in the Han Chinese population","volume":"76","author":"Niu","year":"2015","journal-title":"Hum Immunol"},{"key":"10.1016\/j.kint.2018.10.018_bib66","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2018.10.018_bib67","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1681\/ASN.2014101000","article-title":"Current understanding of the role of complement in IgA nephropathy","volume":"26","author":"Maillard","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib68","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1681\/ASN.2015111210","article-title":"Fine mapping implicates a deletion of CFHR1 and CFHR3 in protection from IgA nephropathy in Han Chinese","volume":"27","author":"Xie","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib69","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1007\/s00467-014-2863-y","article-title":"Eculizumab treatment for rescue of renal function in IgA nephropathy","volume":"29","author":"Rosenblad","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib70","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/ckj\/sfv076","article-title":"Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum?","volume":"8","author":"Ring","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2018.10.018_bib71","first-page":"749","article-title":"Maintenance of remission following completion of OMS721 treatment in patients with IgA nephropathy (IGAN). Abstract SA-PO278","volume":"28","author":"Block","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib72","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib73","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility","volume":"76","author":"Roberts","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib74","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib75","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2015.322","article-title":"The MEST score provides earlier risk prediction in lgA nephropathy","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib76","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1681\/ASN.2016040433","article-title":"A\u00a0multicenter study of the predictive value of crescents in IgA nephropathy","volume":"28","author":"Haas","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib77","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study","volume":"26","author":"Tesar","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib78","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/ki.2011.126","article-title":"Validation of the Oxford classification of IgA nephropathy","volume":"80","author":"Herzenberg","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib79","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2215\/CJN.09710913","article-title":"Association of C4d deposition with clinical outcomes in IgA nephropathy","volume":"9","author":"Espinosa","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib80","series-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource","year":"2016"},{"key":"10.1016\/j.kint.2018.10.018_bib81","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.10.018_bib82","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1681\/ASN.2017060713","article-title":"Effects of two immunosuppressive treatment protocols for IgA nephropathy","volume":"29","author":"Rauen","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib83","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2215\/CJN.02300215","article-title":"Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy","volume":"11","author":"Sarcina","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib84","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib85","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","article-title":"Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial","volume":"20","author":"Frisch","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.10.018_bib86","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","article-title":"Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy","volume":"66","author":"Hogg","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.10.018_bib87","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.10.018_bib88","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/ndt\/gfu020","article-title":"A\u00a0multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy","volume":"29","author":"Kawamura","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.10.018_bib89","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000441852","article-title":"Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy","volume":"132","author":"Feehally","year":"2016","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2018.10.018_bib90","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ki.2013.210","article-title":"Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease","volume":"84","author":"Barbour","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib91","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0002-9343(01)00659-3","article-title":"The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria","volume":"110","author":"Szeto","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.kint.2018.10.018_bib92","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1681\/ASN.2012010063","article-title":"Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria","volume":"23","author":"Gutierrez","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib93","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ki.2009.499","article-title":"Long-term study of mycophenolate mofetil treatment in IgA nephropathy","volume":"77","author":"Tang","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.10.018_bib94","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A\u00a0randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib95","first-page":"748","article-title":"Short-term anti-proteinuric effect of tacrolimus is not related to preservation of glomerular filtration rate during 5 year-follow up period in IgA nephropathy. Abstract SA-PO272","volume":"28","author":"Yu","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib96","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.10.018_bib97","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.10.018_bib98","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.10.018_bib99","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1681\/ASN.2016020114","article-title":"MHC class II risk alleles and amino acid residues in idiopathic membranous nephropathy","volume":"28","author":"Cui","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib100","doi-asserted-by":"crossref","first-page":"e104936","DOI":"10.1371\/journal.pone.0104936","article-title":"The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2018.10.018_bib101","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib102","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1681\/ASN.2014010091","article-title":"Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues","volume":"25","author":"Hofstra","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib103","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2017070734","article-title":"Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy","volume":"29","author":"Seitz-Polski","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib104","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.autrev.2015.10.004","article-title":"Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN)","volume":"15","author":"Radice","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.kint.2018.10.018_bib105","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrneph.2013.125","article-title":"Treatment of idiopathic membranous nephropathy","volume":"9","author":"Hofstra","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib106","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1080\/17512433.2016.1225497","article-title":"Pharmacological treatment of primary membranous nephropathy in 2016","volume":"9","author":"van de Logt","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.kint.2018.10.018_bib107","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/nep.12569","article-title":"Tacrolimus combined with corticosteroids versus modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial","volume":"21","author":"Ramachandran","year":"2016","journal-title":"Nephrology"},{"key":"10.1016\/j.kint.2018.10.018_bib108","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.autrev.2016.12.005","article-title":"Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: a systematic review and meta-analysis of 21 clinical trials","volume":"16","author":"Qiu","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.kint.2018.10.018_bib109","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","article-title":"Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial","volume":"381","author":"Howman","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.10.018_bib110","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib111","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of\u00a0membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.10.018_bib112","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818308093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818308093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:50:19Z","timestamp":1758761419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253818308093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":111,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0085253818308093"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2018.10.018","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2018.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}